A carregar...
OTUD7B upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer
Paclitaxel is a first-line chemotherapeutic for patients with breast cancer, particularly triple-negative breast cancer (TNBC). Molecular markers for predicting pathologic responses to paclitaxel treatment is thus urgently needed since paclitaxel resistance is still a clinical issue in treating TNBC...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5787489/ https://ncbi.nlm.nih.gov/pubmed/29416635 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23074 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|